Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzon Pharmaceuticals (Enzon) has treated first patient in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar (irinotecan HCl injection).
Subscribe to our email newsletter
Enzon said that the study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
Ivan Horak, president of research and development at Enzon, said: “We are excited about the potential PEG-SN38 can have in the pediatric setting. Given PEG-SN38’s safety profile and the unmet medical need in pediatric patients, this compound may play an important role in the future treatment of children who have cancer.”